1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Arbor Pharmaceuticals, Inc. - Product Pipeline Review - 2013

Arbor Pharmaceuticals, Inc. - Product Pipeline Review - 2013

  • October 2013
  • -
  • Global Markets Direct
  • -
  • 18 pages

Arbor Pharmaceuticals, Inc. - Product Pipeline Review - 2013

Summary

Global Market Direct’s pharmaceuticals report, “Arbor Pharmaceuticals, Inc. - Product Pipeline Review - 2013” provides data on the Arbor Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Arbor Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Arbor Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Arbor Pharmaceuticals, Inc. - Brief Arbor Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Arbor Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Arbor Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Arbor Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Arbor Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Arbor Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Arbor Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Arbor Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Arbor Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Table Of Contents

Arbor Pharmaceuticals, Inc. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
Arbor Pharmaceuticals, Inc. Snapshot 4
Arbor Pharmaceuticals, Inc. Overview 4
Key Information 4
Key Facts 4
Arbor Pharmaceuticals, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Arbor Pharmaceuticals, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Arbor Pharmaceuticals, Inc. - Pipeline Products Glance 9
Arbor Pharmaceuticals, Inc. - Late Stage Pipeline 9
Phase III Products/Combination Treatment Modalities 9
Arbor Pharmaceuticals, Inc. Clinical Stage Pipeline Products 10
Phase I Products/Combination Treatment Modalities 10
Arbor Pharmaceuticals, Inc. - Drug Profiles 11
AR-05 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
AR-06 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
AR-08 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
Arbor Pharmaceuticals, Inc. - Pipeline Analysis 14
Arbor Pharmaceuticals, Inc. - Pipeline Products by Therapeutic Class 14
Arbor Pharmaceuticals, Inc. - Dormant Projects 15
Arbor Pharmaceuticals, Inc. - Locations And Subsidiaries 16
Head Office 16
Appendix 17
Methodology 17
Coverage 17
Secondary Research 17
Primary Research 17
Expert Panel Validation 17
Contact Us 18
Disclaimer 18



List of Tables

Arbor Pharmaceuticals, Inc., Key Information 4
Arbor Pharmaceuticals, Inc., Key Facts 4
Arbor Pharmaceuticals, Inc. - Pipeline by Indication, 2013 6
Arbor Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 7
Arbor Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 8
Arbor Pharmaceuticals, Inc. - Phase III, 2013 9
Arbor Pharmaceuticals, Inc. - Phase I, 2013 10
Arbor Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, 2013 14
Arbor Pharmaceuticals, Inc. - Dormant Developmental Projects,2013 15



List of Figures

Arbor Pharmaceuticals, Inc. - Pipeline by Indication, 2013 6
Arbor Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 7
Arbor Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 8
Arbor Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, 2013 14

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.